A blood-based biomarker of body-wide inflammation called a low systemic immune-inflammation index (SII) before a standard Kasai surgical procedure can accurately predict post-surgery liver…
Six months of Calliditas Therapeutics‘ investigational therapy setanaxib safely and significantly reduced signs of liver damage in people with hard-to-treat primary biliary cholangitis…
Dosing has begun in a Phase 2 clinical trial evaluating the safety and efficacy of DD01 in people with one of two forms of fatty…
In its efforts to connect diagnosed but untreated hepatitis B or C patients with physicians, the Center for Disease Analysis (CDA) Foundation has…
Children with biliary atresia show developmental problems, including language delays, following a living donor liver transplant (LDLT) in infancy and a second surgery to…
A living donor liver transplant successfully managed liver failure in a 6-month-old boy with progressive familial intrahepatic cholestasis type 8 (PFIC8) that was unresponsive to…
Clinical genome sequencing, or cGS, testing to detect a rare genetic disease such as Alagille syndrome, resulted in a positive diagnosis of varying disorders…
A team of researchers, backed by a grant totaling more than $3 million, will study the feasibility of a nationwide opt-out testing program to detect…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to larsucosterol, Durect’s investigational therapy for people with severe alcohol-associated hepatitis…
One year of treatment with Gilead Sciences’ seladelpar normalized biomarkers of liver injury and rapidly reduced itch for most people with primary biliary…
